Investigating treatments for newborns experiencing opioid withdrawal
Thomas Jefferson University Hospital Clinical Site for HEAL NOWS Pharmacologic Trial
This study is looking at how well different medications help newborns with opioid withdrawal, and it's for families with babies aged 0-4 weeks who are going through this tough time, with lots of support provided along the way.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10916560 on NIH RePORTER |
What this research studies
This research focuses on evaluating the effectiveness of different pharmacological treatments for Neonatal Opioid Withdrawal Syndrome (NOWS) in infants aged 0-4 weeks. Conducted at Thomas Jefferson University Hospital, the project aims to optimize care for newborns affected by opioid withdrawal through clinical trials that assess medications like buprenorphine. The research team has extensive experience in this area and will also collect genetic samples to enhance understanding of treatment responses. Families will receive comprehensive support throughout the process, ensuring both maternal and infant health are prioritized.
Who could benefit from this research
Good fit: Ideal candidates for participation are infants aged 0-4 weeks who are experiencing symptoms of opioid withdrawal.
Not a fit: Patients who are not newborns or those not affected by opioid withdrawal will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for newborns suffering from opioid withdrawal, enhancing their recovery and overall health outcomes.
How similar studies have performed: Previous research has shown success in similar approaches, particularly in optimizing pharmacological treatments for NOWS, indicating a strong foundation for this trial.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Kraft, Walter K — Thomas Jefferson University
- Study coordinator: Kraft, Walter K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.